In particular, NCL could represent a novel opportunity to improve management of elderly AML patients, not only as an original and independent prognostic factor useful to guide therapy choices but also as novel therapeutic target to develop innovative strategy dedicated to a particular elderly patients subgroup. Here, NUCLEOLIN is linked to acute myeloid leukemia.